Aclaris Therapeutics, Inc. (ACRS) vs Immix Biopharma, Inc. (IMMX)

A side-by-side comparison of Aclaris Therapeutics, Inc. and Immix Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aclaris Therapeutics, Inc. logo
ACRS
Aclaris Therapeutics, Inc.
$559M
$4.00HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
Immix Biopharma, Inc. logo
IMMX
Immix Biopharma, Inc.
$541M
$9.95HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

Total return — ACRS vs IMMX

growth of $100 · dividends reinvested · last 5y
ACRS -68.9% (-20.8%/yr)IMMX +176.0% (+22.5%/yr)IMMX compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020222023202420252026$31$276
ACRS IMMX

ACRS vs IMMX: by the numbers

  • •ACRS is the larger company ($559M vs $541M market cap).
  • •Both run net losses; IMMX's is the smaller (0.00% vs -921.50% net margin).

Metrics side by side

Valuation

MetricACRSIMMX
P/S ratio67.97N/A
P/B ratio4.482.36

Profitability

MetricACRSIMMX
Gross margin73.28%0.00%
Operating margin-975.91%0.00%
Net margin-921.50%0.00%
ROE-60.79%-17.44%
ROIC-56.99%-18.20%

Growth (annualized)

MetricACRSIMMX
Revenue CAGR (5Y)4.39%N/A
Total return CAGR (5Y)-24.23%N/A

Go deeper

Full ACRS analysisFull IMMX analysisInteractive comparison tool

Dig into the metrics

Aclaris Therapeutics ROEImmix Biopharma ROEAclaris Therapeutics operating marginImmix Biopharma operating marginAclaris Therapeutics revenue growthImmix Biopharma revenue growthAclaris Therapeutics free cash flowImmix Biopharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.